ACET - Adicet Bio, Inc.

7.57
0.550   7.266%

Share volume: 135,962
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$7.02
0.55
0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 40%
Dept financing 22%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.84%
1 Month
17.55%
3 Months
1,317.07%
6 Months
950.95%
1 Year
765.04%
2 Year
226.29%
Key data
Stock price
$7.57
P/E Ratio 
N/A
DAY RANGE
$7.09 - $7.60
EPS 
-$1.28
52 WEEK RANGE
$0.45 - $9.05
52 WEEK CHANGE
$794.80
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
153.256 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$84,130
AVERAGE 30 VOLUME 
$183,862
Company detail
CEO: Chen Schor
Region: US
Website: adicetbio.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Recent news